HROW Harrow Health Inc
Company Analysis
Latest News
🔴 Harrow Health is trading 7.5% down with no clear company-specific catalyst
Harrow Health is trading 7.5% lower at $28.22, in line with healthcare-sector weakness. - Healthcare was down 1.49% amid geopolitical and rate concerns. - No...
Harrow Completes Acquisition of TYRVAYA® Dry Eye Nasal Spray for $30M Upfront
Harrow, Inc. announced it has completed the acquisition of the worldwide rights (excluding Japan) to TYRVAYA®, a nasal spray for dry eye disease, from Viatris...
🔴 Harrow Health is trading 5.2% down today amid broad market pressure
Harrow Health is trading 5.2% lower at $31.35 amid broader market pressure; no direct cause for its September 28 move has been established. - Major indexes...
🔴 Harrow Health is trading 5% down today
Harrow Health is trading 5% down at $34.70, with no clearly identified company-specific catalyst. - Extends its decline from $36.58 on September 10, 2026. -...
🟢 Harrow Health is trading 5% up today after BlackRock disclosed 7.35% ownership
Harrow Health is trading 5% up now at $38.84 after investors reacted to BlackRock’s disclosed 2,740,117-share position. - The position is valued at...
BlackRock buys $116M stake in Harrow, boosting institutional ownership to 73%
BlackRock Inc. acquired 2,740,117 shares of Harrow, Inc. during the second quarter. The new position is valued at approximately $116.37 million according to a...
🔴 Harrow Health is trading 5% down today; specific catalyst remains unclear
Harrow Health is trading now at $39.23, down 5.08%, with no new company-specific announcement or analyst action identified for August 26, 2026. - Latest...
🟢 Harrow Health is trading 5.4% up today as Nasdaq Composite rises 0.54%
Harrow Health is trading at $41.94, up +5.38%, outperforming as the Nasdaq Composite rises 0.54% and the broader market remains positive on August 25, 2026. -...
Harrow Health IHEEZO cuts injection pain by 58 percent, topping proparacaine
Harrow Health reported positive results from an investigator-initiated study of its IHEEZO ophthalmic gel. The study evaluated patients receiving same-day...
🟢 Harrow Health is trading 6.4% up today amid a 3.23% healthcare-sector advance
Harrow Health is trading at $41.92, up +6.40% on August 19, 2026, amid sector rotation and stronger healthcare sentiment alongside a 3.23% healthcare-sector...
🟢 Harrow Health is trading 5.71% up today after upgrade to cautious Buy
Harrow Health is trading 5.71% up at $41.09 on August 14, 2026, after a recent upgrade from Hold to a cautious Buy. - The upgrade cited improved...
🔴 Harrow Health is trading 5.7% down today after a wider-than-expected adjusted Q2 loss
Harrow Health is trading $38.38 (-5.69%) after its August 10 earnings release showed a wider-than-expected adjusted loss of $0.46 per share and revenue of...
Harrow Health's Eye Drug Sales Are Surging, So Why Did the Stock Just Lose a Tenth of Its Value
Shares of Harrow Health cratered 9.1% to $36.98 after the eye-drug specialist posted second-quarter results Monday evening that deepened the market's concerns...
🔴 Harrow Health is trading 9.1% down in pre-market after larger-than-expected Q2 loss and revenue miss
Harrow Health is trading 9.13% down at $36.98 after its August 10 second-quarter earnings release showed a larger-than-expected loss and slight revenue...
🔴 Harrow Health is trading 5.2% down in after-hours trading after revenue and adjusted EPS missed expectations
Harrow Health is trading 5.2% down now at $38.58 in after-hours trading after August 10, 2026, second-quarter results missed revenue and adjusted EPS...
Harrow's second quarter 2026 VEVYE revenue beat expectations despite overall revenue and EPS miss
Harrow reported second quarter 2026 revenue of $70.7 million, missing analyst estimates of $72.4 million, while producing a larger-than-expected adjusted EPS...
Harrow Health Inc Q2 2026 Earnings Preview: What Analysts Expect on August 10, 2026
For Q2 2026, analysts anticipate Harrow Health will report revenue of $72.42 million and an EPS loss of $0.23, with the current stock price of $62.15 trading...
Harrow to Acquire Global Rights to TYRVAYA from Viatris for up to $100M
Harrow, Inc. has entered into a definitive agreement with Viatris Inc. to acquire the global rights to TYRVAYA®, a nasal spray for the treatment of dry eye...
Harrow Relaunches First Lucentis Biosimilar, Targeting $9 Billion US Market
Harrow has launched BYOOVIZ® (ranibizumab-nuna) in the United States. The product is the first FDA-approved biosimilar to Genentech’s Lucentis®. Samsung...
🟢 Harrow Health is trading 5.4% up today as it rebounds from recent weakness with no clear catalyst identified
Harrow Health is trading at $39.49 (5.4% up) in after-hours trading, rebounding from recent weakness observed over the past week. • No fresh company-specific...